Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian P Mander

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Trials|March 8, 2020
Designs for adding a treatment arm to an ongoing clinical trialMaxine Bennett, Adrian P Mander
Obesity (Silver Spring, Md.)|October 15, 2013
How to use published complete case results from weight loss studies in a missing data sensitivity analysisLynne Cresswell, Adrian P Mander
Pharmaceutical Statistics|March 14, 2012
Escalation strategies for combination therapy Phase I trialsMichael J Sweeting, Adrian P Mander
JCO Precision Oncology|December 24, 2021
Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported AdequatelyMichael J Grayling, Adrian P Mander
Journal of Biopharmaceutical Statistics|February 23, 2022
Optimised point estimators for multi-stage single-arm phase II oncology trialsMichael J Grayling, Adrian P Mander
Statistics in Medicine|January 30, 2015
A product of independent beta probabilities dose escalation design for dual-agent phase I trialsAdrian P Mander, Michael J Sweeting
The Stata Journal|December 9, 2024
Calculations involving the multivariate normal and multivariate t distributions with and without truncationMichael J Grayling, Adrian P Mander
Contemporary Clinical Trials|June 3, 2021
Accounting for variation in the required sample size in the design of group-sequential trialsMichael J Grayling, Adrian P Mander
BMC Medical Research Methodology|January 30, 2019
Re-formulating Gehan's design as a flexible two-stage single-arm trialMichael J Grayling, Adrian P Mander
Pharmaceutical Statistics|November 27, 2015
Do single-arm trials have a role in drug development plans incorporating randomised trials?Michael J Grayling, Adrian P Mander
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Trials|March 8, 2020
Designs for adding a treatment arm to an ongoing clinical trialMaxine Bennett, Adrian P Mander
Obesity (Silver Spring, Md.)|October 15, 2013
How to use published complete case results from weight loss studies in a missing data sensitivity analysisLynne Cresswell, Adrian P Mander
Pharmaceutical Statistics|March 14, 2012
Escalation strategies for combination therapy Phase I trialsMichael J Sweeting, Adrian P Mander
JCO Precision Oncology|December 24, 2021
Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported AdequatelyMichael J Grayling, Adrian P Mander
Journal of Biopharmaceutical Statistics|February 23, 2022
Optimised point estimators for multi-stage single-arm phase II oncology trialsMichael J Grayling, Adrian P Mander
Statistics in Medicine|January 30, 2015
A product of independent beta probabilities dose escalation design for dual-agent phase I trialsAdrian P Mander, Michael J Sweeting
The Stata Journal|December 9, 2024
Calculations involving the multivariate normal and multivariate t distributions with and without truncationMichael J Grayling, Adrian P Mander
Contemporary Clinical Trials|June 3, 2021
Accounting for variation in the required sample size in the design of group-sequential trialsMichael J Grayling, Adrian P Mander
BMC Medical Research Methodology|January 30, 2019
Re-formulating Gehan's design as a flexible two-stage single-arm trialMichael J Grayling, Adrian P Mander
Pharmaceutical Statistics|November 27, 2015
Do single-arm trials have a role in drug development plans incorporating randomised trials?Michael J Grayling, Adrian P Mander
Pageof 8